An analysis from the FDA Adverse Event Reporting System (FAERS), involving 20,516 patients, identified a higher rate of EGFR TKI-associated interstitial lung disease (ILD) in NSCLC patients who had received prior nivolumab treatment [57], aligning with findings from other clinical and preclinical studies [58,59,60]. This evidence concerns the gene EGFR and interstitial lung disease.